Allergan, Serenity Pharmaceuticals announce global agreement for nocturia drug development Allergan, Inc. and Serenity Pharmaceuticals, Today announced a global agreement for the advancement and commercialization of Ser-120 LLC, a Phase III investigational drug presently in clinical advancement for the treatment of nocturia, a common yet often under-diagnosed urological disorder in adults seen as a frequent urination during the night time.S. Option of Addyi for HSDD treatment in premenopausal womenESPU, ICCS release World Bedwetting Day time to improve awareness among children and familiesUnder the conditions of the contract, Allergan receives exclusive world-wide rights to develop, manufacture and commercialize Ser-120. The contract encompasses all potential indications except Primary Nocturnal Enuresis .At the beginning of the 21st Century, the IFBB attempted to initiate body building recognition of bodybuilding as a sport in the Olympics. The attempt saw IFBB obtain complete IOC membership in the entire year 2000. Further attempts to have the approval for a demonstration event status at the Olympic Games, which was hoped to result in its acknowledgement as a valid contest, failed. Olympic level reputation for body building has up to now remained extremely controversial mainly because many critics argue that bodybuilding is alone not a sporting activity.
AIUM announces Presidential Reputation Awards for exceptional services to ultrasound community Alfred Z.